Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569387 · ClinicalTrials.gov registry record · Phase 2
Vaccine Study for Surgically Resected Pancreatic Cancer
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00569387 is a Phase 2 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 73 participants.
The verdict
NCT00569387, a Phase 2 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.
Interventions
- BIOLOGICAL HyperAcute(R)-Pancreatic Cancer Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569387
The ClinicalTrials.gov registry entry for NCT00569387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HyperAcute(R)-Pancreatic Cancer Vaccine is the first listed.
NCT00569387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569387 about?
NCT00569387 is a clinical study titled "Vaccine Study for Surgically Resected Pancreatic Cancer". To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.
What is the current status of trial NCT00569387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2007-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00569387?
The interventions under investigation include: HyperAcute(R)-Pancreatic Cancer Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00569387?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.